MENU

Development of phototherapeutic agent for lung cancer using novel chlorin compounds

Novel chlorin e6-based medicine (photosensitiser) to efficiently treat skin cancer has been approved by rada-pharma in russia.

It is still necessary to further research, even though significant progress in diagnosis and therapy for lung cancer has continuously been made. The present therapy for lung cancer is non-tumour specific such as surgical section, chemotherapy and radiotherapy or combinations of these. However the 5-year survival rate of the present methodology is mostly below 15%. Developing a new therapeutic strategy is one of the highest levels of work, since revealing the molecular mechanism of lung cancer does not allow for extending survival. Many novel techniques such as immune therapy, cellular therapy and gene therapy have been developed in many advanced countries as next generation therapy. Photodynamic therapy in particular has been applied increasingly as a non-surgical technique and tumour specific therapy. Presently PDT (Photodynamic Therapy) has been limited to some early types of endobronchial lung cancer or superficial tumours due to the physicochemical limitation of the 1st generation photosensitiser, Photofrin, although it can be used in some obstructive late stage tumours showing only a partial response from Photofrin-PDT. Radachlorin, developed by RADA-PHARMA and approved as Photodynamic Therapy (PDT) drug for skin cancer in RUSSIA, has the following advantages over the conventional 1st generation PDT drug, Photofrin: deeper tissue penetration due to longer absorption wavelength (662 nm compared to 635 nm of Photofrin), short tissue uptake time (3 h post-injection compared to 48 h of Photofrin), short body retent time (just 1-2 days compared to 1-2 months of Photofrin), no infection risk due to plant extract as the origin of raw substances compared to animal blood in the case of Photofrin, and resulting in a competitive low cost for manufacturing. Therefore Radachlorin is a particularly promising candidate as a PDT agent for cancer as indicated already on skin cancer in previous Russian clinical studies. RADA-PHARMA RUSSIA as the primary investigator will produce the Radachlorin substance, and carry out all the necessary manufacturing work including derivatisation, purification, subsequent characterisation and dosaging. LITEPHARMTECH, the Korean partner, is in the middle of progressing KGLP-based preclinical studies of Radachlorin followed by Phase II-III clinical studies to get approval as a medicinal drug from the Korean FDA. RADA-PHARMA INTERNATIONAL B.V., the Dutch partner, is expected to carry out rodent/non-rodent toxicity laboratory safety tests on the basis of GLP according to Dutch/European regulations. In addition, it is going to extend Radachlorin's clinical indication to lung cancer and other cancers in this application in the EUREKA project by collaborating with other partners. Keywords: health, therapy, cancer treatment, photosensitiser.
Acronym: 
RADACHLORIN
Project ID: 
3 974
Start date: 
01-02-2007
Project Duration: 
23months
Project costs: 
1 040 000.00€
Technological Area: 
Pharmaceutical Products / Drugs
Market Area: 
Pharmaceuticals/fine chemicals

Raising the productivity and competitiveness of European businesses through technology. Boosting national economies on the international market, and strengthening the basis for sustainable prosperity and employment.